Effect of leuprolide on serum amyloid-β peptide levels and memory in patients with prostate cancer with biochemical recurrence

Winston Tan, Michael G. Heckman, Prakash Vishnu, Juliana Crook, Linda H. Younkin, Edgar G. Covil, Tanis Jill Ferman, Neill R Graff Radford, Steven G Younkin, Robert Christian Smallridge, Michael J. Wehle, Steven J. Buskirk

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To investigate whether prostate cancer patients receiving leuprolide demonstrated objective cognitive decline accompanied by a change in plasma levels of amyloid-β. Methods: Between November 19, 2003, and July 21, 2008, we prospectively enrolled 50 patients with biochemical recurrence of prostate cancer and measured plasma amyloid-β peptide 40 and amyloid-β peptide 42 levels with sandwich enzyme-linked immunosorbent assay at baseline before the first leuprolide injection and at 2, 4, and 12 months. The Mini-Mental State Examination was used to assess 49 patients at baseline and at subsequent visits, and 24 were also assessed by the California Verbal Learning Test-Short Form. Results: Patients were a median age of 71 years (range, 59-89 years). Compared with baseline levels, plasma amyloid-β peptide 40 levels were increased at 2 months (P =.04) and 4 months (P =.02). Age was correlated with plasma amyloid-β peptide 40 levels (P =.003) and likely accounted for this relationship. Plasma amyloid-β peptide 42 and performance on cognitive tasks did not differ from baseline, but memory measures improved slightly after baseline, most likely due to a practice effect. Conclusion: Leuprolide therapy was not associated with a decline in cognition or memory function or with elevated plasma amyloid short-term. Larger studies are needed to confirm these findings.

Original languageEnglish (US)
Pages (from-to)150-154
Number of pages5
JournalUrology
Volume81
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Leuprolide
Amyloid
Prostatic Neoplasms
Recurrence
Peptides
Serum
Verbal Learning
Cognition
Enzyme-Linked Immunosorbent Assay
Injections

ASJC Scopus subject areas

  • Urology

Cite this

Effect of leuprolide on serum amyloid-β peptide levels and memory in patients with prostate cancer with biochemical recurrence. / Tan, Winston; Heckman, Michael G.; Vishnu, Prakash; Crook, Juliana; Younkin, Linda H.; Covil, Edgar G.; Ferman, Tanis Jill; Graff Radford, Neill R; Younkin, Steven G; Smallridge, Robert Christian; Wehle, Michael J.; Buskirk, Steven J.

In: Urology, Vol. 81, No. 1, 01.2013, p. 150-154.

Research output: Contribution to journalArticle

@article{02bc36ee290647ba8ace9e91bda3a5c9,
title = "Effect of leuprolide on serum amyloid-β peptide levels and memory in patients with prostate cancer with biochemical recurrence",
abstract = "Objective: To investigate whether prostate cancer patients receiving leuprolide demonstrated objective cognitive decline accompanied by a change in plasma levels of amyloid-β. Methods: Between November 19, 2003, and July 21, 2008, we prospectively enrolled 50 patients with biochemical recurrence of prostate cancer and measured plasma amyloid-β peptide 40 and amyloid-β peptide 42 levels with sandwich enzyme-linked immunosorbent assay at baseline before the first leuprolide injection and at 2, 4, and 12 months. The Mini-Mental State Examination was used to assess 49 patients at baseline and at subsequent visits, and 24 were also assessed by the California Verbal Learning Test-Short Form. Results: Patients were a median age of 71 years (range, 59-89 years). Compared with baseline levels, plasma amyloid-β peptide 40 levels were increased at 2 months (P =.04) and 4 months (P =.02). Age was correlated with plasma amyloid-β peptide 40 levels (P =.003) and likely accounted for this relationship. Plasma amyloid-β peptide 42 and performance on cognitive tasks did not differ from baseline, but memory measures improved slightly after baseline, most likely due to a practice effect. Conclusion: Leuprolide therapy was not associated with a decline in cognition or memory function or with elevated plasma amyloid short-term. Larger studies are needed to confirm these findings.",
author = "Winston Tan and Heckman, {Michael G.} and Prakash Vishnu and Juliana Crook and Younkin, {Linda H.} and Covil, {Edgar G.} and Ferman, {Tanis Jill} and {Graff Radford}, {Neill R} and Younkin, {Steven G} and Smallridge, {Robert Christian} and Wehle, {Michael J.} and Buskirk, {Steven J.}",
year = "2013",
month = "1",
doi = "10.1016/j.urology.2012.08.066",
language = "English (US)",
volume = "81",
pages = "150--154",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of leuprolide on serum amyloid-β peptide levels and memory in patients with prostate cancer with biochemical recurrence

AU - Tan, Winston

AU - Heckman, Michael G.

AU - Vishnu, Prakash

AU - Crook, Juliana

AU - Younkin, Linda H.

AU - Covil, Edgar G.

AU - Ferman, Tanis Jill

AU - Graff Radford, Neill R

AU - Younkin, Steven G

AU - Smallridge, Robert Christian

AU - Wehle, Michael J.

AU - Buskirk, Steven J.

PY - 2013/1

Y1 - 2013/1

N2 - Objective: To investigate whether prostate cancer patients receiving leuprolide demonstrated objective cognitive decline accompanied by a change in plasma levels of amyloid-β. Methods: Between November 19, 2003, and July 21, 2008, we prospectively enrolled 50 patients with biochemical recurrence of prostate cancer and measured plasma amyloid-β peptide 40 and amyloid-β peptide 42 levels with sandwich enzyme-linked immunosorbent assay at baseline before the first leuprolide injection and at 2, 4, and 12 months. The Mini-Mental State Examination was used to assess 49 patients at baseline and at subsequent visits, and 24 were also assessed by the California Verbal Learning Test-Short Form. Results: Patients were a median age of 71 years (range, 59-89 years). Compared with baseline levels, plasma amyloid-β peptide 40 levels were increased at 2 months (P =.04) and 4 months (P =.02). Age was correlated with plasma amyloid-β peptide 40 levels (P =.003) and likely accounted for this relationship. Plasma amyloid-β peptide 42 and performance on cognitive tasks did not differ from baseline, but memory measures improved slightly after baseline, most likely due to a practice effect. Conclusion: Leuprolide therapy was not associated with a decline in cognition or memory function or with elevated plasma amyloid short-term. Larger studies are needed to confirm these findings.

AB - Objective: To investigate whether prostate cancer patients receiving leuprolide demonstrated objective cognitive decline accompanied by a change in plasma levels of amyloid-β. Methods: Between November 19, 2003, and July 21, 2008, we prospectively enrolled 50 patients with biochemical recurrence of prostate cancer and measured plasma amyloid-β peptide 40 and amyloid-β peptide 42 levels with sandwich enzyme-linked immunosorbent assay at baseline before the first leuprolide injection and at 2, 4, and 12 months. The Mini-Mental State Examination was used to assess 49 patients at baseline and at subsequent visits, and 24 were also assessed by the California Verbal Learning Test-Short Form. Results: Patients were a median age of 71 years (range, 59-89 years). Compared with baseline levels, plasma amyloid-β peptide 40 levels were increased at 2 months (P =.04) and 4 months (P =.02). Age was correlated with plasma amyloid-β peptide 40 levels (P =.003) and likely accounted for this relationship. Plasma amyloid-β peptide 42 and performance on cognitive tasks did not differ from baseline, but memory measures improved slightly after baseline, most likely due to a practice effect. Conclusion: Leuprolide therapy was not associated with a decline in cognition or memory function or with elevated plasma amyloid short-term. Larger studies are needed to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=84871987185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871987185&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2012.08.066

DO - 10.1016/j.urology.2012.08.066

M3 - Article

VL - 81

SP - 150

EP - 154

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -